Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Fig. 3

Kaplan-Meier survival curves of patients stratified by VEGF-121 plasma level in patients with recurrent GB after treatment with bevacizumab methylation status. The lower level of VEGF-121 (L-VEGF-121) are significantly associated with a favorable survival advantage in term of OS (a; p = 0.0246; HR 15.34; 95% CI from 1.418 to 166.0) and PFS (b; p = 0.0295; HR 16.23; 95% CI from 1.320 to 199.6) in comparison with those recurrent GBs with higher level (H-VEGF-121)

Back to article page